.png)
Quick answer: Australia's R&D Tax Incentive offers eligible biotech companies a refundable tax offset of up to 48% on qualifying clinical trial expenditure, making it one of the most competitive R&D incentive programmes globally and significantly more generous than the approximately 6% federal R&D tax credit available in the US. The 2026/27 Federal Budget introduced significant reforms including lifting the refundable threshold to $50 million aggregated turnover for companies under ten years old. The incentive is genuinely compelling for both Australian and international startups running Phase I, II, or III trials. But the companies that extract full value from it are the ones that integrate commercial and market access thinking into their clinical programme from the beginning, not after the data is in.
There is a reason international biotech companies have been quietly running their early-phase clinical trials in Australia for over two decades. Australia's R&D Tax Incentive allows companies to receive a tax offset of up to 48% on clinical trial related R&D costs under the 2026/27 Federal Budget reforms, and with over two decades of experience delivering early-phase trials, Australia has positioned its specialist ecosystem as the preferred destination for international biotech companies. For context, the equivalent R&D tax credit in the US sits at approximately 6%, making the Australian incentive one of the most competitive in the world for early-phase clinical development. Combined with fast ethics approval timelines and a mature clinical infrastructure, the cost advantage at the stage of development when most startups have the least capital to burn is material.
What gets discussed less is the other side of the equation: what all of that investment needs to produce to translate into commercial success. Failure in biotech often has little to do with the science and is more related to a clear commercial direction, and it is tragic to see good potential assets fail because there is no clarity from the beginning about not only the timeline, but the funding. The R&D Tax Incentive can extend a startup's runway meaningfully. But runway is only valuable if the programme is headed somewhere commercially defensible.
What the 2026/27 Budget Changes Actually Mean for Biotech Startups
The Federal Budget announced in May 2026 introduced the most significant restructure of the RDTI since 2020, and for early-stage biotech companies the reforms are largely positive, with some important caveats.
The refundable R&D tax offset threshold lifts from $20 million to $50 million aggregated turnover, and the core offset rate increases to roughly 48% from 43.5%. For an early-stage company spending AUD $2 million on a Phase I trial in Australia, that is approximately AUD $960,000 back, a meaningful extension of clinical runway that, for companies capitalised in USD, is further amplified by the exchange rate.
Under the updated framework, eligible biotech companies under ten years old can continue accessing refundable R&D support so long as their aggregate turnover is under $50 million, a 150% increase to the cap from previous years. That ten-year age threshold is worth noting carefully. Companies that have been operating for more than a decade may retain access to the higher offset rate but lose the refundable component, carrying losses forward instead. For startups approaching that threshold, understanding the timing implications of their RDTI strategy is a financial planning question, not just a tax question.
From 1 July 2028, supporting R&D activities will no longer be eligible under Australia's R&D Tax Incentive. This is the change that is most underestimated, and it can be a material part of many claims. For biotech companies running clinical trials with significant process development, formulation work, or manufacturing activities around their core IP, the supporting activities change reduces the claimable base in ways that will not become visible until the new rules apply. Auditing existing RDTI claims against the 2028 framework now is considerably less painful than discovering the exposure later.
The Clinical Trial Eligibility Rules and Why Phase Matters
Not all clinical trial activity qualifies under the RDTI, and the phase of the trial matters more than most early-stage founders realise.
Clinical trials at Phase 0, I, II, and III undertaken in Australia are likely to meet the criteria for the Australian R&D Tax Incentive as core R&D activities, provided they meet the experimental activity requirements. Phase IV clinical trials are not eligible as core R&D activities if they are being carried out to meet regulatory requirements, though where they are being carried out as experiments for the purpose of resolving further medical research studies, and eligibility requirements are met, Phase IV clinical trials may be eligible.
The experimental purpose requirement is worth taking seriously. For core R&D activities, clinical trials must be run with the purpose of generating new knowledge about the therapy being investigated. A trial designed primarily to satisfy a TGA or FDA regulatory requirement, rather than to generate genuinely new scientific knowledge, may not qualify as a core R&D activity regardless of the phase. The programme design matters, and getting it right at the protocol stage is considerably cheaper than unpicking it during an ATO compliance review.
In 2026, the ATO is zeroing in on documentation, ability to meet eligibility requirements, and high-risk claims, with large or amended claims likely to face extra scrutiny. For biotech companies making substantial clinical trial claims, the documentation standard has risen. Programme design rationale, experimental hypotheses, and knowledge generation objectives need to be recorded contemporaneously, not reconstructed at the end of the financial year.
What TGA and FDA Require When Your Data Is Generated Offshore
This is where the clinical trial location decision becomes strategically more complex than the tax incentive alone would suggest.
Running trials in Australia to access the RDTI is sensible if Australia is one of your target markets, or if you are using it as an efficient early-phase jurisdiction before running larger international studies. The complications arise when a company treats Australia as a standalone clinical jurisdiction and then discovers, later in development, that neither the TGA nor the FDA will accept data generated outside their respective frameworks without additional conditions being met.
The FDA has an expectation that products filed for marketing authorisation include data that are representative of the US patient population. Any foreign clinical data that is submitted has to represent an ethnically diverse population generated using qualified Principal Investigators and conducted according to Good Clinical Practices outlined in 21 CFR 312.120. That means an Australian Phase II trial conducted in a predominantly Anglo-Celtic patient population may not adequately represent the US population for the purposes of an FDA submission, even if the trial was rigorously conducted and the data are robust.
Marketing approval of a new drug based solely on foreign clinical data has faced increasing scrutiny from the FDA, which has clarified its stance that applications for drugs not supported by multiregional trials face a higher bar. For biotech companies planning a US market entry, the implication is that trials designed to maximise RDTI eligibility in Australia need to be simultaneously designed to meet FDA data diversity and GCP requirements, or the US programme will need to repeat work already done, at considerably more cost.
The TGA operates under a different framework but carries its own local requirements. A company seeking TGA registration for a novel therapeutic will need to demonstrate that the evidence package addresses the Australian patient population and regulatory standard, which may not be identical to the international data package already generated. Understanding the TGA's expectations at the point of clinical programme design, rather than at the point of submission preparation, saves material time and money. Our guide to TGA permitted indications and how to choose, map and defend yours covers the evidence requirements in more detail.
Why Science-Led Biotechs Often Get the Commercial Sequencing Wrong
Many biotech startups emerge from strong academic or translational science but lack the operational, regulatory, and capital market strategy required to sustain long development timelines, and many underestimate the cost and time to reach key value inflection points such as IND filing or Phase II proof of concept. This is the structural challenge that sits underneath everything else in this post.
The R&D Tax Incentive, used well, extends runway. Good clinical trial design, aligned with TGA and FDA data requirements, produces data packages that can support regulatory submissions. Both of those things are necessary. Neither of them is sufficient to produce a commercially successful drug. Separating regulatory strategy from commercial strategy can kill an otherwise promising biotech, because the two need to be developed together from the beginning rather than in sequence.
The questions that commercial and market access strategy needs to answer: what is the target indication, what patient population, what clinical benefit over existing standard of care, what reimbursement pathway, what pricing strategy, and what partnership or exit thesis are not questions that can be deferred until after Phase II. They shape the clinical programme design. A trial designed to demonstrate statistically significant efficacy in the broadest possible patient population may produce data that is scientifically impressive and commercially ambiguous. A trial designed with the reimbursement endpoint and the payer audience in mind, from the protocol stage, produces data that tells a specific commercial story.
Having clarity from the beginning is going to enable the company to understand not only the timeline, but the funding, and all the gaps experienced in that process are exactly the reason we do not have more treatments available. For science-led founders, bringing in commercial and market access perspective early does not compromise scientific rigour, it focuses it. Our piece on evidence strategy for health and wellness brands covers how the same principle applies across the broader health and wellness category.
The Practical Checklist Before Committing to an Australian Clinical Programme
For any biotech startup (Australian or international) considering Australia as a clinical trial jurisdiction, these are the questions worth working through before the protocol is finalised.
On RDTI eligibility: Does the trial design meet the experimental purpose requirement for a core R&D activity? Are the activities being claimed genuinely generating new scientific knowledge, or primarily meeting a regulatory requirement? Will any supporting activities that currently form part of the claimable base be affected by the 2028 changes? Is the company within the ten-year age threshold for the refundable offset?
On regulatory data acceptability: If the US is a target market, does the trial population adequately represent the diversity requirements in 21 CFR 312.120? Are the Principal Investigators qualified to generate FDA-acceptable data? Has the programme design been reviewed against TGA requirements for the specific indication and pathway being pursued?
On commercial strategy: What is the target indication and the patient population the trial is designed to serve? What does the evidence package need to demonstrate to support a reimbursement submission in the primary target markets? What is the partnership or exit thesis, and what data milestones are required to support it? Is there a payer strategy, and has it informed the choice of primary and secondary endpoints?
None of these questions are complicated to ask. Answering them well, before the protocol is finalised and the site agreements are signed, is where the value is created.
Further reading
This piece connects to several other topics covered in depth on the Parallaxis Insights blog. For a closer look at how TGA evidence requirements work for therapeutic goods, see our guide to TGA permitted indications and how to choose, map and defend yours. For the commercial claim strategy questions that arise once a product is approaching market, our piece on evidence strategy for health and wellness brands covers the methodology in detail.
Frequently asked questions
How does Australia's R&D Tax Incentive work for clinical trials?
Australia's R&D Tax Incentive provides eligible companies with a refundable tax offset on qualifying R&D expenditure. For biotech companies, Phase I, II, and III clinical trials conducted in Australia are generally eligible as core R&D activities, provided they are designed to generate new scientific knowledge rather than primarily to meet a regulatory requirement. The 2026/27 Federal Budget proposed increasing the core offset rate to approximately 48% from 43.5%, with the refundable threshold lifted to $50 million aggregated turnover for companies under ten years old.
How does Australia's R&D Tax Incentive compare to the US R&D tax credit?
Australia's refundable R&D tax offset for eligible clinical trial expenditure sits at approximately 48% under the 2026/27 Federal Budget reforms, compared to approximately 6% for the US federal R&D tax credit. The Australian incentive is also refundable for eligible companies, meaning loss-making startups receive it as a cash payment rather than a credit against future tax liability. Combined with Australia's competitive clinical trial costs and fast ethics approval timelines, the gap in incentive value is material for early-stage companies making jurisdiction decisions.
Can international biotech companies access Australia's R&D Tax Incentive?
Yes. International biotech companies conducting eligible R&D activities in Australia can access the R&D Tax Incentive, provided they meet the eligibility requirements including having an Australian tax presence through a subsidiary or registered entity. Multi-centre trials that include Australian sites, even as part of a broader international programme, can be eligible for the Australian portion of expenditure. The incentive has made Australia one of the preferred destinations for international sponsors running early-phase trials.
Will data from Australian clinical trials be accepted by the FDA for a US drug application?
Australian clinical trial data can be submitted to the FDA under 21 CFR 312.120, which governs foreign clinical studies not conducted under an IND. However, the FDA expects that data submitted in support of a US marketing application represents the US patient population, including ethnic diversity requirements. A trial conducted solely in Australia may not satisfy those requirements without additional data from US or multiregional sites. Programme design should account for FDA data acceptability requirements from the outset rather than at the submission stage.
What changed in the 2026/27 Federal Budget for the R&D Tax Incentive?
The 2026/27 Federal Budget proposed the most significant restructure of the RDTI since 2020, taking effect from 1 July 2028. Key changes include lifting the refundable offset turnover threshold from $20 million to $50 million for companies under ten years old, increasing the core offset rate to approximately 48%, removing eligibility for supporting R&D activities, and increasing the R&D expenditure cap from $150 million to $200 million. The removal of supporting activities eligibility is the change most likely to reduce claimable bases for companies running clinical programmes with significant process development or manufacturing activities.
Why should biotech startups involve commercial strategy in clinical programme design?
The choice of primary and secondary endpoints, the patient population enrolled, the comparator used, and the study duration all carry commercial implications that affect reimbursement submissions, payer negotiations, and partnership value. Bringing commercial and market access perspective in at the protocol stage does not compromise scientific rigour — it focuses it toward producing evidence that tells a specific commercial story as well as a scientific one. Companies that defer commercial strategy until after Phase II consistently face longer and more expensive paths to market.
How Parallaxis helps
The R&D Tax Incentive is a financial tool. What it funds needs to be doing commercial work from the beginning. Parallaxis works with early-stage biotech companies and their development teams to build the commercial and evidence strategy that sits alongside the clinical programme, identifying the claims architecture the data package needs to support, mapping the regulatory pathway to the target markets, and ensuring the evidence being generated now will hold up under the scrutiny that matters most when it counts. If you are designing a clinical programme and want a commercial perspective in the room before the protocol is finalised, get in touch.